ATE348159T1 - Mutierte mitglieder der tgf-beta-superfamilie, einschliesslich morphogenetischer proteine - Google Patents

Mutierte mitglieder der tgf-beta-superfamilie, einschliesslich morphogenetischer proteine

Info

Publication number
ATE348159T1
ATE348159T1 AT99954770T AT99954770T ATE348159T1 AT E348159 T1 ATE348159 T1 AT E348159T1 AT 99954770 T AT99954770 T AT 99954770T AT 99954770 T AT99954770 T AT 99954770T AT E348159 T1 ATE348159 T1 AT E348159T1
Authority
AT
Austria
Prior art keywords
tgf
proteins
beta superfamily
morphogenetic proteins
members
Prior art date
Application number
AT99954770T
Other languages
English (en)
Inventor
Hermann Oppermann
Mei-Sheng Tai
John Mccartney
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Application granted granted Critical
Publication of ATE348159T1 publication Critical patent/ATE348159T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99954770T 1998-10-07 1999-10-07 Mutierte mitglieder der tgf-beta-superfamilie, einschliesslich morphogenetischer proteine ATE348159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10341898P 1998-10-07 1998-10-07
US09/374,936 US6846906B1 (en) 1998-10-07 1999-08-16 Modified proteins of the TGF-β superfamily, including morphogenic proteins

Publications (1)

Publication Number Publication Date
ATE348159T1 true ATE348159T1 (de) 2007-01-15

Family

ID=26800440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99954770T ATE348159T1 (de) 1998-10-07 1999-10-07 Mutierte mitglieder der tgf-beta-superfamilie, einschliesslich morphogenetischer proteine

Country Status (8)

Country Link
US (1) US6846906B1 (de)
EP (1) EP1117795B1 (de)
JP (2) JP3982995B2 (de)
AT (1) ATE348159T1 (de)
AU (1) AU772934B2 (de)
CA (1) CA2345287C (de)
DE (1) DE69934418T2 (de)
WO (1) WO2000020591A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919308B2 (en) * 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US7524625B2 (en) * 2000-10-30 2009-04-28 Sru Biosystems, Inc. Real time binding analysis of antigens on a biosensor surface
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
JP5100662B2 (ja) * 2005-12-22 2012-12-19 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
US7659250B2 (en) 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
US20100184659A1 (en) 2006-12-21 2010-07-22 Warren Jaworowicz Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
EP2019117A1 (de) * 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimiertes Reinigungsverfahren für rekombinantes Wachstumsfaktorprotein
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
US20100204124A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
US8952130B2 (en) * 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
AU2015374114B2 (en) 2014-12-29 2018-07-26 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
JP7562082B2 (ja) 2018-11-05 2024-10-07 味の素株式会社 フローマイクロリアクターを用いるリフォールディングされたタンパク質の製造方法及びタンパク質のリフォールディング装置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250302A (en) 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
DE68929472T2 (de) 1988-04-08 2004-05-13 Stryker Corp., Kalamazoo Biosynthetische knochenbildende Proteine, und sie enthaltende knochenbildende Vorrichtungen
US5304541A (en) 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
ES2118723T3 (es) 1989-10-17 1998-10-01 Stryker Corp Dispositivos osteogenicos.
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
ATE194169T1 (de) 1990-11-16 2000-07-15 Celtrix Pharma Beta-type ähnlicher transformierender wachstumfaktor
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
EP0690871A4 (de) 1993-01-12 1999-10-20 Univ Johns Hopkins Med Wachstums-differenzierungsfaktor-5
CA2124422A1 (en) 1993-05-27 1994-11-28 Yukio Fujisawa Heterodimers of tgf-.beta. superfamily
CA2165776A1 (en) 1993-07-09 1995-01-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
WO1996014335A1 (en) * 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5674292A (en) 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)

Also Published As

Publication number Publication date
JP2002526111A (ja) 2002-08-20
CA2345287A1 (en) 2000-04-13
AU1103700A (en) 2000-04-26
WO2000020591A3 (en) 2000-07-06
JP3982995B2 (ja) 2007-09-26
DE69934418D1 (de) 2007-01-25
JP2005287515A (ja) 2005-10-20
EP1117795B1 (de) 2006-12-13
CA2345287C (en) 2011-12-06
DE69934418T2 (de) 2007-10-25
WO2000020591A2 (en) 2000-04-13
AU772934B2 (en) 2004-05-13
WO2000020591A9 (en) 2001-03-22
EP1117795A2 (de) 2001-07-25
US6846906B1 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
DE69934418D1 (de) MUTIERTE MITGLIEDER DER TGF-BETA-SUPERFAMILIE, EINSCHLIEßLICH MORPHOGENETISCHER PROTEINE
ATE364704T1 (de) Mutanten von op-1
DE69220084D1 (de) Diagnostische Anwendungen der Bildung von doppelten D-Loops.
EP1322307A4 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
AU6147096A (en) Use of nucleic acid ligands in flow cytometry
ATE325892T1 (de) Multiparameter fluoreszenz in situ hybridisierung
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
ATE369434T1 (de) Adenoassoziierte virusvektoren und ihre verwendungen
ATE395417T1 (de) Pestizid toxine
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
SE8902532D0 (sv) Bestaemning av plasmaproteiner
ZA986475B (en) Thermodynamically stable modification of 1-(4-carbazoly loxy)3-[2-)2-methoxyphenoxy)ethylamino]-2-propanole, and pharmaceutical compositions containing it.
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
EP1312684A3 (de) Quantitative Multiplex-PCR mit grossem Dynamikbereich
ATE227561T1 (de) Verwendung von alpha-alkylglucosiden und deren estern als antimikrobielle emulgatoren
FR2781481B1 (fr) Nouveaux 2-amino, 4-alkylamino pyrimidine 3-oxydes et composition les comprenant
FR2834216B1 (fr) Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
DE59814032D1 (de) Nucleinsäuremolekül, kit und verwendung
DE69938774D1 (de) Verfahren zur isolierung, amplifizierung und charakterisierung von dns
ATE416782T1 (de) Medizinische verwendung von il-174 agonisten und antagonisten
ZA200007321B (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.
ATE349702T1 (de) Nachweis und quantifizierung von cripto-1
ATE417926T1 (de) Zusammensetzungen zur modulierung der länge von telomeren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties